During the conference call, Neoprobe's President and CEO, David Bupp, and Vice President and CFO, Brent Larson, will provide a business update and discuss the Company's results for the second quarter and first half of 2009.
The conference call can be accessed as follows:
Conference Call Information
TO PARTICIPATE LIVE: TO LISTEN TO A REPLAY:
Date: August 12, 2009 Available until: August 19, 2009
Time: 11:00 AM ET Toll-free (U.S.) Dial in # : 877-660-6853
International Dial in # : 201-612-7415
Toll-free (U.S.) Dial in # : 877-407-8033 Replay Passcodes:
International Dial in # : 201-689-8033 Account # : 286
Conference ID # : 329964
About Neoprobe
Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe(R) GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek(R) and RIGScan(R) CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com
SOURCE: Neoprobe Corporation
Neoprobe Corporation Brent Larson, Vice President / CFO, 614-822-2330 OR The Shoreham Group Tim Ryan, 646-342-6199 tryan@shorehamgroupllc.com

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index